Navigation Links
Skin transplant offers new hope for vitiligo patients

DETROIT Henry Ford Hospital dermatologists say skin transplant surgery is safe and effective for restoring skin pigmentation caused by the skin disease vitligo.

In a first study of its kind in the United States, researchers followed 23 patients for up to six months after surgery and found that the treated area regained on average 43 percent of its natural skin color. In eight patients with localized vitiligo, the treated area regained on average 68 percent of its natural skin color.

The surgery involves using skin cells taken from healthy, normally pigmented areas of the body and transferring them to the damaged area of skin. It is performed under local anesthesia.

The study is published in the May edition of the Journal of the American Academy of Dermatology. It is available online at

"The results achieved in our study were of obvious significance to our patients," says Iltefat Hamzavi, M.D., a senior staff physician in Henry Ford's Department of Dermatology and the study's senior author and principal investigator. "We believe this new treatment option offers hope to patients of color and those with vitiligo on one side of the body or in one area of the body."

Vitiligo is a skin disease that causes the skin to lose color and develop white patches that vary in size and location. It affects about 1 in every 200 people in the United States, and is more noticeable in people with darker skin. Standard treatments include light therapy and topical medications.

Vitiligo develops when cells called melanocytes are killed by the body's immune system, causing the area of skin to turn white because the cells no longer make pigment. While there is no cure, vitiligo can be treated and managed with light therapy, creams and topical medications.

The surgery is known as melanocyte-keratinocyte transplantation, or MKTP, and is performed in Europe, Asia and the Middle East. It was performed at Henry Ford using the same technique developed by MKTP pioneer Sanjeev Mulekar, M.D., of the National Vitiligo Center in Saudi Arabia. Henry Ford is the first to perform MKTP in North America.

In Henry Ford's study, 28 patients underwent surgery and ranged in age from 18 to 60. A total of 36 MKTP procedures were performed and researchers analyzed the outcomes of 29 of them. The procedure lasted 30 minutes to two hours and patients returned home the same day.

Of the 28 surgery patients, 23 were followed for up to six months after surgery. Eighteen patients received one treatment, four patients received two and one patient received three. The ethnicity of patients was Caucasian, South Asian, African American and Hispanic.

During MKTP, melanocyte cells, which produce pigment in the skin, hair and eyes, are harvested from an area of healthy skin and separated to make a skin cell mixture. This mixture then is applied to the treatment area and covered with a specially developed adhesive biologic dressing.

Treated areas included the hands, arms, legs, feet, face and stomach. The average size of the treated area during each procedure was 46 cm2, or roughly the size of a credit card.


Contact: David Olejarz
Henry Ford Health System

Related medicine news :

1. New drug for kidney transplant recipients effective in humans
2. WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday
3. Spanish Only, Please: Special Latino Clinic Launched For Potential Abdominal Transplant Patients
4. WellPoint/Blue Cross Liver Transplant Denial Trial Begins Today, Illustrates Need for Toughening of White House Reform Plan
5. Newer cornea transplant surgery shows short- and long-term promise
6. Cristophe Salon in Beverly Hills Teams Up with Mad Men Actor to Help Raise Money for His 17-Year-Old Cousins Heart Transplant
7. Two Babies Born a Year Apart After Ovary Transplant
8. Wounded Soldier Who Received Historic Cell Transplant Gets Standing Ovation at Diabetes Research Institute Benefit
9. Internal Anthem Blue Cross/WellPoint Document: Only Patients Who Push Back Get Covered Out of State Liver Transplants
10. Drug dramatically reduces nausea and vomiting in bone marrow transplant patients
11. Kidney Patients From Across South Carolina Visit State Capitol to Encourage Policies that Improve Patient Access to Life-Saving Dialysis and Transplant Care
Post Your Comments:
Related Image:
Skin transplant offers new hope for vitiligo patients
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology: